Pasithea Therapeutics
KTTA
6 hedge funds and large institutions have $218K invested in Pasithea Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
130% more capital invested
Capital invested by funds: $94.7K → $218K (+$123K)
2.83% more ownership
Funds ownership: 0.06% → 2.89% (+2.8%)
25% less funds holding
Funds holding: 8 → 6 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$197K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.15K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$48.8K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$17.4K |
| 3 |
Renaissance Technologies
New York
|
-$12K |
| 4 |
Jane Street
New York
|
-$8.73K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
ADAR1 Capital Management
Austin,
Texas
| $201K | +$197K | +27,696 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $9.75K | +$5.15K | +725 | +117% |
|
|
3
UBS Group
Zurich,
Switzerland
| $4.41K | +$4.32K | +608 | New |
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | – | – | – |
|
5
JP Morgan Chase
New York
| $1.09K | – | – | – |
|
6
Wells Fargo
San Francisco,
California
| $44 | – | – | – |
|
|
7
Geode Capital Management
Boston,
Massachusetts
| – | -$48.8K | -6,256 | Closed |
|
|
8
Northern Trust
Chicago,
Illinois
| – | -$17.4K | -2,354 | Closed |
|
|
9
Renaissance Technologies
New York
| – | -$12K | -1,625 | Closed |
|
|
10
Jane Street
New York
| – | -$8.73K | -1,179 | Closed |
|
KTTA Hedge Fund Activity: Q1 2024 in Review
6 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q1 2024, worth a combined $218K — up 130% from $94.7K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of KTTA and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $197K. The largest seller was Geode Capital Management, exiting entirely with an estimated $48.8K sold.
- 6 institutional investors held Pasithea Therapeutics (KTTA) as of Q1 2024, down from 8 in Q4 2023.
- Funds reported $218K of Pasithea Therapeutics stock for Q1 2024, up 130% quarter-over-quarter.
- 2 funds opened new Pasithea Therapeutics positions in Q1 2024 and 4 closed out, a net change of -2 holders.
- The largest Pasithea Therapeutics buyer in Q1 2024 was ADAR1 Capital Management, an estimated $197K added.
- The largest Pasithea Therapeutics seller in Q1 2024 was Geode Capital Management, an estimated $48.8K sold.
Based on aggregated 13F filings for Q1 2024.